Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Monday, December 23rd.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock opened at $4.81 on Friday. The firm has a 50-day moving average price of $4.86 and a two-hundred day moving average price of $5.19. The firm has a market capitalization of $280.46 million, a price-to-earnings ratio of -17.18 and a beta of 0.76. Vanda Pharmaceuticals has a 52-week low of $3.46 and a 52-week high of $6.75.

Insider Transactions at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the sale, the director now owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Meeder Asset Management Inc. purchased a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at $39,000. ORG Wealth Partners LLC purchased a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at about $40,000. China Universal Asset Management Co. Ltd. raised its stake in Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $75,000. Finally, Intech Investment Management LLC purchased a new position in shares of Vanda Pharmaceuticals during the third quarter worth approximately $84,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.